Choi Eun Young, Christianson Gregory J, Yoshimura Yoshitaka, Sproule Thomas J, Jung Nadja, Joyce Sebastian, Roopenian Derry C
The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.
Immunity. 2002 Nov;17(5):593-603. doi: 10.1016/s1074-7613(02)00428-4.
The H60 minor histocompatibility (H) antigen peptide is derived from a glycoprotein that serves as a ligand for the stimulatory NKG2D receptor. We show that this peptide is remarkably immunodominant in that it competes effectively with MHC alloantigens, is efficiently crosspresented by host antigen-presenting cells (APCs), and readily elicits naive CD8 T cell responses in vitro. H60 immunodominance is neither a consequence of NKG2D engagement nor competition among minor H antigens on APCs. Instead, H60 immunodominance is a consequence of an abnormally high naive precursor frequency of H60 peptide reactive CD8 T cells. Understanding why the H60 peptide is so immunogenic has important implications in tissue transplantation and vaccine design.
H60次要组织相容性(H)抗原肽源自一种糖蛋白,该糖蛋白作为刺激性NKG2D受体的配体。我们发现,这种肽具有显著的免疫显性,因为它能与MHC同种异体抗原有效竞争,能被宿主抗原呈递细胞(APC)高效交叉呈递,并且在体外容易引发初始CD8 T细胞反应。H60的免疫显性既不是NKG2D参与的结果,也不是APC上次要H抗原之间竞争的结果。相反,H60的免疫显性是H60肽反应性CD8 T细胞初始前体频率异常高的结果。了解H60肽为何具有如此强的免疫原性对组织移植和疫苗设计具有重要意义。